← Back to Search

Atypical Antipsychotic

Medication + Cognitive Training for Schizophrenia

Phase 4
Recruiting
Led By Dante Durand, MD
Research Sponsored by University of Miami
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Adults with a diagnosis of schizophrenia
Currently hospitalized or experiencing outpatient relapse
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

Study Summary

This trial looks at how stable mental health affects recovery from schizophrenia in those newly diagnosed.

Who is the study for?
This trial is for adults with schizophrenia who have been hospitalized or relapsed as outpatients fewer than four times. They must be willing to take long-acting injectable medication and participate in rehabilitation but cannot have had prior treatment resistance, previous long-acting injections, or be unable to consent.Check my eligibility
What is being tested?
The study tests whether Aripiprazole Lauroxil (a long-acting injectable antipsychotic) combined with computerized cognitive training can help patients with early-stage schizophrenia recover functionally when they are clinically stable.See study design
What are the potential side effects?
Aripiprazole Lauroxil may cause weight gain, restlessness, insomnia, headache, anxiety, nausea or vomiting. The computerized training has no physical side effects but could potentially lead to frustration or fatigue.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with schizophrenia.
Select...
I am currently in the hospital or having a relapse without being admitted.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
The percentage of participants who develop sustained remission of symptoms of schizophrenia as measured as having a score of 3 or less on all 6 critical items from the Positive and Negative Syndrome Scale (PANSS)

Trial Design

1Treatment groups
Experimental Treatment
Group I: Aripiprazole and Computerized Cognitive and Functional Skills Training GroupExperimental Treatment2 Interventions
Participants in this arm will receive long-acting injectable aripiprazole every 2 months formulation for 12 consecutive months. Participants in this arm will also receive Computerized cognitive and functional skills training during the first 12 weeks of study participation.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Aripiprazole Lauroxil
2014
Completed Phase 4
~440

Find a Location

Who is running the clinical trial?

Alkermes, Inc.Industry Sponsor
113 Previous Clinical Trials
26,676 Total Patients Enrolled
22 Trials studying Schizophrenia
6,038 Patients Enrolled for Schizophrenia
University of MiamiLead Sponsor
897 Previous Clinical Trials
409,199 Total Patients Enrolled
3 Trials studying Schizophrenia
509 Patients Enrolled for Schizophrenia
Dante Durand, MDPrincipal InvestigatorUniversity of Miami Miller School

Media Library

Aripiprazole Lauroxil (Atypical Antipsychotic) Clinical Trial Eligibility Overview. Trial Name: NCT05662306 — Phase 4
Schizophrenia Research Study Groups: Aripiprazole and Computerized Cognitive and Functional Skills Training Group
Schizophrenia Clinical Trial 2023: Aripiprazole Lauroxil Highlights & Side Effects. Trial Name: NCT05662306 — Phase 4
Aripiprazole Lauroxil (Atypical Antipsychotic) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05662306 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What potential dangers do Aripiprazole and Computerized Cognitive and Functional Skills Training Group pose for patients?

"As this is a Phase 4 clinical trial, our team has assigned Aripiprazole and Computerized Cognitive and Functional Skills Training Group a score of 3 on the safety scale. This indicates that it is approved for use in medical treatments."

Answered by AI

Are there any available slots in this experiment for participants?

"According to clinicaltrials.gov, this medical study has concluded its patient recruitment period. Initially posted on June 1st 2023 and last updated December 14th 2022, the trial no longer requires volunteers but there are a plethora of other studies that still require participants right now."

Answered by AI
~40 spots leftby May 2025